Opioid withdrawal suppression efficacy of oral dronabinol in opioid dependent humans
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Background The cannabinoid (CB) system is a rational novel target for treating opioid dependence, a significant public health problem around the world. This proof-of-concept study examined the potential efficacy of a CB1 receptor partial agonist, dronabinol, in relieving signs and symptoms of opioid withdrawal. Methods Twelve opioid dependent adults participated in this 5-week, inpatient, double-blind, randomized, placebo-controlled study. Volunteers were maintained on double-blind oxycodone (30mg oral, four times/day) and participated in a training session followed by 7 experimental sessions, each testing a single oral test dose (placebo, oxycodone 30 and 60mg, dronabinol 5, 10, 20, and 30mg [decreased from 40mg]). Placebo was substituted for oxycodone maintenance doses for 21 hours before each session in order to produce measurable opioid withdrawal. Outcomes included observer- and participant-ratings of opioid agonist, opioid withdrawal and psychomotor/cognitive performance. Results Oxycodone produced prototypic opioid agonist effects (i.e., suppressing withdrawal and increasing subjective effects indicative of abuse liability). Dronabinol 5 and 10mg produced effects most similar to placebo, while the 20 and 30mg doses produced modest signals of withdrawal suppression that were accompanied by dose-related increases in high, sedation, bad effects, feelings of heart racing, and tachycardia. Dronabinol was not liked more than placebo, showed some impairment in cognitive performance, and was identified as marijuana with increasing dose. Conclusion CB1 receptor activation is a reasonable strategy to pursue for the treatment of opioid withdrawal; however, dronabinol is not a likely candidate given its modest withdrawal suppression effects of limited duration and previously reported tachycardia during opioid withdrawal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug Dependence, a Chronic Medical Illness
McLellan, A. T., Lewis, D. C., O'Brien, C. P., & Kleber, H. D. (2000) · JAMA · doi:10.1001/jama.284.13.1689 · Cited by 2,622 · cited 2×
“Given the chronic relapsing nature of opioid dependence (McLellan et al., 2000), the continued availability of opioids worldwide, and the substantial number of persons initiating heroin and non-medical opioid analgesic use each year, treatment demand will continue to grow (Cicero et al., 2015; Dart…”
BackgroundEnzymatic pathways that regulate endocannabinoid signaling in the nervous system
Ahn, K., McKinney, M. K., & Cravatt, B. F. (2008) · Chemical Reviews · doi:10.1021/cr0782067 · Cited by 529 · cited 1×
“…of endocannibinoid degradation enzymes, such as fatty acid amide hydrolase (FAAH) and/or monacylglyerol lipase (MAGL), can elevate endogenous cannabinoids to promote CB receptor activation potentially without some of the undesirable effects seen with exogenous CB agonists (Ahn et al., 2008).”
BackgroundHuggins, J. P., Smart, T. S., Langman, S., Taylor, L., & Young, T. (2012) · Pain · doi:10.1016/j.pain.2012.04.020 · Cited by 375 · cited 1×
“However, it is worth noting that BIA-10-2474 was well tolerated at lower doses and other investigational FAAH inhibitors have been tested in Phase I, II and III studies without significant adverse consequences (Huggins et al., 2012; Li et al., 2012; Pawsey et al., 2016).”
BackgroundRios, C., Gomes, I., & Devi, L. A. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706757 · Cited by 327
Cichewicz, D. L., & Welch, S. P. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.046870 · Cited by 110 · cited 1×
“…that exogenous ∆9-THC decreases signs of opioid withdrawal in morphinedependent mice and rats (Hine et al., 1975a, 1975b; Bhargava, 1976,; Lichtman et al., 2001; Cichewicz and Welch, 2003; Gamage et al., 2015), and conversely, CB1 antagonists precipitate opioid withdrawal (Scavone et al., 2013).”
BackgroundDifferential effects of endocannabinoid catabolic inhibitors on morphine withdrawal in mice
Gamage, T. F., Ignatowska-Jankowska, B. M., Muldoon, P. P., Cravatt, B. F., Damaj, M. I., & Lichtman, A. H. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.11.015 · Cited by 40 · cited 2×
“Other studies have demonstrated that exogenous ∆9-THC decreases signs of opioid withdrawal in morphinedependent mice and rats (Hine et al., 1975a, 1975b; Bhargava, 1976,; Lichtman et al., 2001; Cichewicz and Welch, 2003; Gamage et al., 2015), and conversely, CB1 antagonists precipitate opioid withdrawal (Scavone et al.”
Background
Cited by
Bilbao, A., & Spanagel, R. (2022) · BMC Medicine · doi:10.1186/s12916-022-02459-1 · Cited by 181
How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review
Hoch, E., Niemann, D., von Keller, R., Schneider, M., Friemel, C. M., Preuss, U. W., Hasan, A., & Pogarell, O. (2019) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-019-00984-4 · Cited by 131
Clinical Management of Opioid Withdrawal.
Torres‐Lockhart, K. E., Lu, T. Y., Weimer, M. B., Stein, M. R., & Cunningham, C. O. (2022) · Addiction · doi:10.1111/add.15818 · Cited by 57
Spanagel, R., & Bilbao, A. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108680 · Cited by 43
Tapering opioids: a comprehensive qualitative review
Davis, M. P., Digwood, G., Mehta, Z., & McPherson, M. L. (2020) · Annals of Palliative Medicine · doi:10.21037/apm.2019.12.10 · Cited by 33
Metadata
- Authors
- Lofwall, M. R., Babalonis, S., Nuzzo, P. A., Elayi, S. C., & Walsh, S. L.
- Venue
- Drug and Alcohol Dependence
- Publisher
- Elsevier BV
- Published
- 2016-07
- Volume
- 164
- Pages
- 143-150
- ISSN
- 0376-8716 (ISSN-L)
- OpenAlex
- W2392691276
- Cited by
- 70
- References
- 6
- FWCI
- 1.59
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Opioid withdrawal suppression efficacy of oral dronabinol in opioid dependent humans. https://app.cochat.ai/papers/10.1016/j.drugalcdep.2016.05.002
- The paper
- Lofwall, M. R., Babalonis, S., Nuzzo, P. A., Elayi, S. C., & Walsh, S. L. (2016). Opioid withdrawal suppression efficacy of oral dronabinol in opioid dependent humans. Drug and Alcohol Dependence. https://doi.org/10.1016/j.drugalcdep.2016.05.002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.